Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1291583 mass balance and pharmacokinetics study in healthy men
NL-OMON60526Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of verducatib, sponsored by Boehringer Ingelheim. Primary endpoints: feurine, 0-tz, fefaeces, 0-tz and 2 more. Started Apr 2023; status: completed.
02
Drugs
verducatib
Beyond the preview
Go deeper on NL-OMON60526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60526.